ketoconazole has been researched along with atorvastatin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C | 1 |
| Bizot, MN; Camenisch, G; Dieterich, HA; Dole, WP; Howard, D; Reynolds, C; Schuetz, H; Vaidyanathan, S; Yeh, CM | 1 |
| Ando, H; Araki, N; Enosawa, S; Fujimura, A; Hasegawa, G; Nagai, H; Omasa, T; Tsuruoka, S; Wang, N; Yanagihara, H | 1 |
| Bodmer, M; Brecht, K; Bur, D; Krähenbühl, S; Tsakiris, DA; Zahno, A | 1 |
| Chang, JH; Cheong, J; Ly, J; Messick, K; Plise, E; Wright, M; Zhang, X | 1 |
| Dwi Cahyadi, D; Irie, N; Ishikawa, T; Sugiura, A; Tashiro, J; Warita, K; Warita, T | 1 |
2 review(s) available for ketoconazole and atorvastatin
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for ketoconazole and atorvastatin
| Article | Year |
|---|---|
Atorvastatin--a new lipid-lowering drug.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Ketoconazole; Pyrroles | 1997 |
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Topics: Adult; Amides; Animals; Antifungal Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Female; Fumarates; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Organic Anion Transporters; Pyrroles; Renin; Tissue Distribution; Young Adult | 2008 |
10 other study(ies) available for ketoconazole and atorvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes | 1999 |
Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
Topics: Ammonia; Animals; Atorvastatin; Cell Line, Tumor; Cricetinae; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glutamate-Ammonia Ligase; Heptanoic Acids; Humans; Ketoconazole; Lidocaine; Nifedipine; Pyrroles | 2008 |
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Clarithromycin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Models, Molecular; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrroles; Recombinant Proteins; Simvastatin; Substrate Specificity; Ticlopidine | 2010 |
Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.
Topics: Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HEK293 Cells; Heptanoic Acids; Humans; Ketoconazole; Liver; Mice; Mice, Knockout; Organic Anion Transport Protein 1; Pyrroles; Rifampin | 2014 |
CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin.
Topics: Atorvastatin; Cell Line, Tumor; Cholesterol; Cholesterol Side-Chain Cleavage Enzyme; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Prostatic Neoplasms, Castration-Resistant | 2023 |